{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TDF+placebo", "query": { "intervention": "TDF placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 115, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TDF+placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T15:49:22.603Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03547908", "title": "Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1/HBV Co-Infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" }, { "name": "Placebo to match DTG", "type": "DRUG" }, { "name": "Placebo to match F/TDF", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" }, { "name": "F/TDF", "type": "DRUG" }, { "name": "Placebo to match B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2018-05-30", "completion_date": "2024-03-07", "has_results": true, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-09-03T15:49:22.603Z", "location_count": 4, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Berkley", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547908" }, { "nct_id": "NCT01108510", "title": "Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "COBI placebo", "type": "DRUG" }, { "name": "RTV placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 698, "start_date": "2010-04", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-23", "last_synced_at": "2026-09-03T15:49:22.603Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01108510" }, { "nct_id": "NCT00869557", "title": "Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" }, { "name": "Atripla", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2009-04", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-09-03T15:49:22.603Z", "location_count": 30, "location_summary": "Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869557" }, { "nct_id": "NCT05719441", "title": "A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute HIV Infection" ], "interventions": [ { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "PGT121.414.LS", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "ART", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 48, "start_date": "2024-08-19", "completion_date": "2028-09-06", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-03T15:49:22.603Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05719441" }, { "nct_id": "NCT01797445", "title": "Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "E/C/F/TDF Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 872, "start_date": "2013-03-12", "completion_date": "2018-10-03", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-09-03T15:49:22.603Z", "location_count": 79, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01797445" }, { "nct_id": "NCT04652700", "title": "Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Preexposure Prophylaxis" ], "interventions": [ { "name": "ISL", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "FTC/TAF", "type": "DRUG" }, { "name": "Placebo to ISL", "type": "DRUG" }, { "name": "Placebo to FTC/TDF", "type": "DRUG" }, { "name": "Placebo to FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "MALE", "summary": "16 Years and older · Male only" }, "enrollment_count": 494, "start_date": "2021-03-15", "completion_date": "2023-08-04", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-03T15:49:22.603Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04652700" }, { "nct_id": "NCT02431247", "title": "A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immunodeficiency Virus Type 1, Human" ], "interventions": [ { "name": "Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC", "type": "DRUG" }, { "name": "DRV/COBI FDC", "type": "DRUG" }, { "name": "FTC/TDF FDC", "type": "DRUG" }, { "name": "D/C/F/TAF FDC - Matching Placebo", "type": "DRUG" }, { "name": "FTC/TDF FDC Matching Placebo", "type": "DRUG" }, { "name": "DRV/COBI FDC Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Sciences Ireland UC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 725, "start_date": "2015-07-06", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-09-03T15:49:22.603Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431247" }, { "nct_id": "NCT02607956", "title": "Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DTG", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "DTG Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 657, "start_date": "2015-11-11", "completion_date": "2021-07-05", "has_results": true, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-09-03T15:49:22.603Z", "location_count": 74, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607956" }, { "nct_id": "NCT02235662", "title": "Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV", "Contraception" ], "interventions": [ { "name": "TFV IVR", "type": "DRUG" }, { "name": "TFV/LNG IVR", "type": "DRUG" }, { "name": "Placebo IVR", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "CONRAD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 86, "start_date": "2014-10", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-01-11", "last_synced_at": "2026-09-03T15:49:22.603Z", "location_count": 1, "location_summary": "Norfolk, Virginia", "locations": [ { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02235662" }, { "nct_id": "NCT01227824", "title": "A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I" ], "interventions": [ { "name": "GSK1349572 (dolutegravir)", "type": "DRUG" }, { "name": "raltegravir", "type": "DRUG" }, { "name": "GSK1349572 Placebo", "type": "OTHER" }, { "name": "ABC/3TC", "type": "OTHER" }, { "name": "TDF/FTC", "type": "OTHER" }, { "name": "raltegravir Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 828, "start_date": "2010-10-19", "completion_date": "2016-12-27", "has_results": true, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-09-03T15:49:22.603Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01227824" } ] }